Skip to content

Transition From Pediatric to Adult Cystic Fibrosis Care Center

Clinical Impact of the Transition From Pediatric to Adult Cystic Fibrosis Care Center

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02790879
Acronym
SAFETIM RNM
Enrollment
300
Registered
2016-06-06
Start date
2015-10-31
Completion date
2016-10-31
Last updated
2016-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Keywords

Transitional care, teenagers, cystic fibrosis, pulmonary function, nutritional function, Patients who experiment a transition pediatric - adult care

Brief summary

The main objective of register-SAFETIM is to assess the impact of the transition from pediatric to adult cystic fibrosis care center on changes in lung function and nutritional status of patients. This is a multicenter, observational, longitudinal, with analysis of the French national registry data of patients with cystic fibrosis. Our study will assess the clinical features of adolescent patients with cystic fibrosis during the transition from pediatric care to adult care. It will explore factors associated with the impact of the transition on the clinical course of adolescent patients (respiratory and nutritional functions).

Interventions

OTHERTransition pediatric - adult

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- patients who switched from pediatric cystic fibrosis care center to an adult cystic fibrosis care center during 2013 or 2014, regardless of their clinical status.

Exclusion criteria

\- Patients whose transition year is not given in the French national register, that is to say patients from some mixed care center.

Design outcomes

Primary

MeasureTime frame
Changes in FEV (FEV is the slope expressed in percentage of the predicted value).Two years

Secondary

MeasureTime frame
Body Mass Index (BMI)Two years
Pseudomonas aeruginosa colonizationTwo years
External pancreatic insufficiencyTwo years
DiabetesTwo years

Countries

France

Contacts

Primary ContactStéphanie POUPON-BOURDY
stephanie.poupon-bourdy@chu-lyon.fr(0)4 72 11 54 16
Backup ContactSandrine TOUZET, MD
sandrine.touzet@chu-lyon.fr(0)4 72 11 51 62

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026